Billiontoone (BLLN) Stock Price, News & Analysis

Company Overview

BillionToOne, Inc. (NASDAQ:BLLN) is a molecular diagnostics company that develops blood-based genetic tests designed to provide more information from small amounts of cell-free DNA. The company’s platform uses proprietary molecular counting technology to improve the sensitivity and accuracy of diagnostic testing.

BillionToOne’s primary business is reproductive health testing. Its UNITY portfolio is designed to support prenatal screening, including testing for chromosomal conditions and single-gene disorders, and is intended to provide physicians and expectant parents with information from a maternal blood sample. The company also develops oncology applications that use cell-free DNA to help detect and monitor cancer-related genetic changes.

Founded in 2016, BillionToOne is headquartered in California and primarily serves healthcare providers and patients in the United States. The company was founded by Oguzhan O. and has been led by him as chief executive officer. Its testing services are offered through clinical laboratories and healthcare channels rather than as consumer products sold directly through retail outlets.

Key Stats

• Today's Range: $96.21 to $102.57
• 50-Day Range: $87.99 to $124.90
• 52-Week Range: $61.96 to $150.44
• Volume: 605,635 shs
• Average Volume: 654,157 shs
• Market Capitalization: $4.63 billion
• P/E Ratio: 140.17
• Dividend Yield: N/A
• Price Target: $126.25
• Consensus Rating: Moderate Buy

Billiontoone Stock Analysis - MarketRank™

Billiontoone scored higher than 83% of companies evaluated by MarketBeat, and ranked 89th out of 887 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Billiontoone has received a consensus rating of Moderate Buy. The company's average rating score is 2.55, and is based on no strong buy ratings, 7 buy ratings, 3 hold ratings, and 1 sell rating.

Upside Potential

Billiontoone has a consensus price target of $126.25, representing about 28.7% upside from its current price of $98.12.

Amount of Analyst Coverage

Billiontoone has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 30.00%

Earnings Growth

Earnings for Billiontoone are expected to grow by 30.00% in the coming year, from $0.80 to $1.04 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Billiontoone is 146.76, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.70.

Price to Earnings Ratio vs. Sector

The P/E ratio of Billiontoone is 146.76, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.15.

Price to Book Value per Share Ratio

Billiontoone has a P/B Ratio of 9.36. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

12.00% of the float of Billiontoone has been sold short.

Short Interest Ratio / Days to Cover

Billiontoone has a short interest ratio ("days to cover") of 3.88, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Billiontoone has recently increased by 7.34%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Billiontoone does not currently pay a dividend.

Dividend Growth

Billiontoone does not have a long track record of dividend growth.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.17

News Sentiment

Billiontoone has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Billiontoone this week, compared to 4 articles on an average week.

Search Interest

Only 3 people have searched for BLLN on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.

MarketBeat Follows

5 people have added Billiontoone to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Billiontoone insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $26,297,325.00 in company stock.

Percentage Held by Insiders

50.22% of the stock of Billiontoone is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Billiontoone has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 10/16/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Providers & Services
• Sub-Industry: Healthcare Services
• Current Symbol: NASDAQ:BLLN
• CIK: 2070849
• Web: www.billiontoone.com
• Phone: (650) 460-2551
• Fax: N/A
• Employees: 713
• Year Founded: 2016

Price Target and Rating

• Average Price Target for Billiontoone: $126.25
• High Price Target: $150.00
• Low Price Target: $90.00
• Potential Upside/Downside: +28.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.55
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.70
• Trailing P/E Ratio: 140.17
• Forward P/E Ratio: 122.65
• P/E Growth: N/A
• Net Income: $7.45 million
• Net Margins: 8.04%
• Pretax Margin: 9.54%
• Return on Equity: 9.96%
• Return on Assets: 5.35%

Debt

• Debt-to-Equity Ratio: 0.17
• Current Ratio: 11.69
• Quick Ratio: 11.31

Sales & Book Value

• Annual Sales: $305.11 million
• Price / Sales: 15.18
• Cash Flow: $0.31 per share
• Price / Cash Flow: 317.38
• Book Value: $10.48 per share
• Price / Book: 9.36

Miscellaneous

• Outstanding Shares: 47,190,000
• Free Float: 23,490,000
• Market Cap: $4.63 billion
• Optionable: N/A
• Beta: N/A